JANSSEN RESEARCH & DEVELOPMENT, LLC

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study of Lazertinib (JNJ-73841937) in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Lazertinib
Drug: Midazolam
Drug: Rosuvastatin
Drug: Metformin

First Posted Date: 2021-10-13

Last Posted Date: 2022-06-27

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 20

Registration Number: NCT05076877

Locations: 🇺🇸
PRA Health Sciences, Salt Lake City, Utah, United States

A Study of Guselkumab and Golimumab Combination Therapy in Participants With Active Psoriatic Arthritis

Phase 2

Completed

Conditions: Arthritis, Psoriatic

Interventions: Drug: Guselkumab
Drug: Placebo
Drug: Golimumab

First Posted Date: 2021-10-08

Last Posted Date: 2025-01-10

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 91

Registration Number: NCT05071664

Locations: 🇵🇱
WroMedica I Bielicka A Strzalkowska s c, Wroclaw, Poland
🇺🇸
Arizona Arthritis and Rheumatology Research PLLC, Phoenix, Arizona, United States
🇺🇸
Unity Health-White County Medical Center, Searcy, Arkansas, United States

and more 78 locations

A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma

Phase 1

Active, not recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Talquetamab
Drug: Carfilzomib
Drug: Pomalidomide
Drug: Daratumumab SC
Drug: Lenalidomide

First Posted Date: 2021-09-20

Last Posted Date: 2025-01-10

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 166

Registration Number: NCT05050097

Locations: 🇺🇸
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
🇺🇸
Indiana University, Indianapolis, Indiana, United States
🇺🇸
Tennessee Oncology, Nashville, Tennessee, United States

and more 28 locations

A Study of Ustekinumab (STELARA) in Chinese Participants With Moderately to Severely Active Crohn's Disease

Phase 4

Active, not recruiting

Conditions: Crohn Disease

Interventions: Drug: Ustekinumab

First Posted Date: 2021-09-01

Last Posted Date: 2025-01-09

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 182

Registration Number: NCT05029921

Locations: 🇨🇳
Ningbo medical center lihuili hospital, Ningbo, China
🇨🇳
Huashan Hospital Fudan University, Shanghai, China
🇨🇳
Shanghai 10th Peoples Hospital, Shanghai, China

and more 26 locations

A Study of JNJ-75229414 for Metastatic Castration-resistant Prostate Cancer Participants

Phase 1

Active, not recruiting

Conditions: Prostatic Neoplasms

Interventions: Drug: JNJ-75229414
Drug: Bridging Therapy

First Posted Date: 2021-08-26

Last Posted Date: 2025-01-10

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 15

Registration Number: NCT05022849

Locations: 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
🇺🇸
Levine Cancer Institute, Charlotte, North Carolina, United States
🇺🇸
City of Hope Cancer Center, Duarte, California, United States

and more 5 locations

A Study of JNJ-64251330 in Participants With Familial Adenomatous Polyposis

Phase 1

Completed

Conditions: Adenomatous Polyposis Coli

Interventions: Drug: JNJ-64251330

First Posted Date: 2021-08-20

Last Posted Date: 2023-06-02

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 42

Registration Number: NCT05014360

Locations: 🇺🇸
University of Miami, Miami, Florida, United States
🇺🇸
City of Hope, Duarte, California, United States
🇫🇷
Hopital Edouard Herriot - CHU Lyon, Lyon, France

and more 13 locations

A Study Exploring the Use of Challenge Agents in Healthy Volunteers or Participants With a Disease of Interest

Early Phase 1

Completed

Conditions: Healthy

Interventions: Radiation: UVB Challenge

First Posted Date: 2021-08-16

Last Posted Date: 2021-12-10

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 24

Registration Number: NCT05007756

Locations: 🇧🇪
Clinical Pharmacology Unit, Merksem, Belgium

A Study of JNJ-73763989, Pegylated Interferon Alpha-2a and Nucleos(t)Ide Analogs in Participants With Chronic Hepatitis B Virus Infection

Phase 2

Terminated

Conditions: Hepatitis B, Chronic

Interventions: Drug: JNJ-73763989
Drug: PegIFN-alpha-2a
Drug: Tenofovir disoproxil
Drug: TAF
Drug: ETV

First Posted Date: 2021-08-13

Last Posted Date: 2024-03-06

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 1

Registration Number: NCT05005507

Locations: 🇺🇸
I.D. Care, Inc., Hillsborough, New Jersey, United States
🇪🇸
Hosp. Univ. Vall D Hebron, Barcelona, Spain
🇪🇸
Hosp. Univ. Infanta Leonor, Madrid, Spain

and more 9 locations

A Proof-of-concept Study of the Efficacy and Safety of Nipocalimab in Participants With Active Rheumatoid Arthritis

Phase 2

Completed

Conditions: Arthritis, Rheumatoid

Interventions: Other: Placebo
Drug: Nipocalimab

First Posted Date: 2021-08-05

Last Posted Date: 2024-12-09

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 53

Registration Number: NCT04991753

Locations: 🇵🇱
Szpital Uniwersytecki nr 2 im dr Jana Biziela w Bydgoszczy, Bydgoszcz, Poland
🇵🇱
Centrum Medyczne AMED Targowek, Warszawa, Poland
🇪🇸
Hosp Univ A Coruna, A Coruna, Spain

and more 24 locations

A Study of JNJ-78306358 in Participants With Advanced Stage Solid Tumors

Phase 1

Completed

Conditions: Neoplasms

Interventions: Drug: JNJ-78306358

First Posted Date: 2021-08-05

Last Posted Date: 2023-03-24

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 39

Registration Number: NCT04991740

Locations: 🇮🇱
Rambam Medical Center, Haifa, Israel
🇪🇸
Hosp. Univ. Vall D Hebron, Barcelona, Spain
🇮🇱
Sourasky Medical Center, Tel Aviv, Israel

and more 2 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy